36 completed, 25 unknown, 6 terminated, 5 not yet recruiting. 85 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 85 | Completed 36, Unknown 25, Terminated 6, Not yet recruiting 5, Withdrawn 5, Recruiting 4, Suspended 3, Active not recruiting 1 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Inhaled Polymyxin as an Adjunct to Intravenous Therapy in Multidrug Resistant Ventilator-associated Pneumonia in Stroke Patients Inhaled colistin, Saline - Ventilator Associated Pneumonia ( VAP) | Early Phase 1 | Not yet recruiting | Ain Shams University | 78 | 2026-10-10 | 2026-10-08 |
| Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia YHDF placebo, Bacteriophage Placebo, YHDF Drug - Pneumonia | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 250 | 2026-06-01 | 2026-05-29 |
| 3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT Amoxicillin - Community Acquired Pneumonia, Childhood Pneumonia | Early Phase 1 | Not yet recruiting | Khyber Teaching Hospital | 250 | 2026-06-01 | 2026-06-15 |
| iNO300 Therapy in Critically Ill Patients With Pneumonia High dose inhaled nitric oxide, Sham treatment, standard therapy - Critical Illness, Pneumonia | Early Phase 1 | Recruiting | Massachusetts General Hospital | 34 | 2026-02-23 | 2026-05-22 |
| A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli YHDF Drug, YHDF Placebo, Bacteriophage - Pneumonia | Early Phase 1 | Not yet recruiting | Chinese PLA General Hospital | 240 | 2026-02-01 | 2026-01-13 |
| Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC) A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static) - PASC Post Acute Sequelae of COVID-19 | Early Phase 1 | Recruiting | University of California, Davis | 51 | 2025-12-04 | 2026-05-22 |
| The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19 NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH) - COVID-19 | Early Phase 1 | Withdrawn | University of California, Irvine | 2025-06-01 | 2024-11-05 | |
| Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use - Covid19 | Early Phase 1 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 20 | 2025-05-18 | 2026-06-10 |
| Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant KFD1(0µg ), KFD1(20µg), KFD1(40µg) - COVID - 19 | Early Phase 1 | Not yet recruiting | Shanghai Public Health Clinical Center | 60 | 2024-12-30 | 2025-01-10 |
| Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) SARS-CoV-2 omicron virus dose arm 1, SARS-CoV-2 omicron virus dose arm 2, SARS-CoV-2 omicron virus dose arm 3 - SARS-CoV-2 Infection | Early Phase 1 | Completed | Hvivo | 36 | 2024-12-02 | 2025-11-21 |
| Long COVID-19 [11C]CPPC Study [11C]CPPC Injection - COVID Long-Haul | Early Phase 1 | Completed | Johns Hopkins University | 6 | 2024-08-06 | 2026-04-30 |
| Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine - COVID - 19 | Early Phase 1 | Completed | Prince of Songkla University | 36 | 2024-03-01 | 2025-12-04 |
| UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study) INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg - COVID-19 Pandemic, COVID-19 Vaccines | Early Phase 1 | Unknown | Dr. Soetomo General Hospital | 400 | 2024-01-29 | 2024-02-14 |
| Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues Liraglutide Pen Injector [Saxenda], Medication Diary - Multiple Sclerosis, Long COVID | Early Phase 1 | Suspended | University of Chicago | 30 | 2024-01-26 | 2026-03-30 |
| PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine low dose PCV24, high dose PCV24, PPV23 - Streptococcus Pneumoniae Pneumonia | Early Phase 1 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 240 | 2023-11-18 | 2025-06-18 |
| Piloting Virtual Reality Environments to Treat PTSD in Healthcare Workers Virtual Reality Exposure Therapy - Posttraumatic Stress Disorder | Early Phase 1 | Recruiting | Weill Medical College of Cornell University | 20 | 2023-10-05 | 2026-09-16 |
| UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg - COVID-19 Pandemic, COVID-19 Vaccines | Early Phase 1 | Unknown | Dr. Soetomo General Hospital | 250 | 2023-09-19 | 2024-02-22 |
| The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002 LYB002V14, LYB002V14A, LYB002CA - COVID-19 | Early Phase 1 | Unknown | Guangzhou Patronus Biotech Co., Ltd. | 210 | 2023-04-25 | 2023-07-03 |
| SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects APR002, Placebo - COVID-19 | Early Phase 1 | Completed | Global Health Drug Discovery Institute | 42 | 2023-03-20 | 2023-08-02 |
| Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19 MSC-derived exosomes - Long COVID-19 Syndrome | Early Phase 1 | Unknown | Huazhong University of Science and Technology | 80 | 2023-02-15 | 2023-04-14 |
Showing 20 of 85. Sign in to see all of them.
COVID-19 (57) · Pneumonia, Ventilator-Associated (7) · Coronavirus Infections (6) · Post-Acute COVID-19 Syndrome (6) · Community-Acquired Pneumonia (3) · Critical Illness (3) · Respiratory Insufficiency (3) · Dyspnea (2) · Influenza, Human (2) · Pneumonia, Viral (2) · Pulmonary Disease, Chronic Obstructive (2) · Respiratory Tract Infections (2) · Severe Acute Respiratory Syndrome (2) · Stress Disorders, Post-Traumatic (2)
Infections (85) · Lung Diseases (84) · Respiratory Tract Diseases (84) · Respiratory Tract Infections (83) · Virus Diseases (62) · Coronaviridae Infections (61) · Nidovirales Infections (61) · RNA Virus Infections (61) · Pneumonia, Viral (60) · Coronavirus Infections (55) · Pathological Conditions, Signs and Symptoms (22) · Disease Attributes (18) · Pathologic Processes (18) · Chronic Disease (8)
COVID-19 Serotherapy (5) · Hydroxychloroquine (4) · Amoxicillin (3) · Saline Solution (3) · vaksin merah putih - UA SARS-CoV-2 COVID-19 vaccine (3) · Acetylcysteine (2) · Azithromycin (2) · Endotoxins (2) · Lipopolysaccharides (2) · Sodium Chloride (2) · Standard of Care (2) · sinovac COVID-19 vaccine (2) · 2,5-dichloro-4-bromophenol (1) · APR002 (1) · Alanine (1)
Washington University School of Medicine (4) · Dr. Soetomo General Hospital (3) · Ann & Robert H Lurie Children's Hospital of Chicago (2) · Azidus Brasil (2) · Chinese PLA General Hospital (2) · Guangzhou Patronus Biotech Co., Ltd. (2) · Lahore General Hospital (2) · Livzon Pharmaceutical Group Inc. (2) · University of California, Davis (2) · University of Chicago (2) · ASST Fatebenefratelli Sacco (1) · Ain Shams University (1) · Amazon University (1) · Baylor College of Medicine (1) · Binhui Biopharmaceutical Co., Ltd. (1)
United States (33) · China (13) · Brazil (3) · Canada (3) · Indonesia (3) · Mexico (3) · Pakistan (3) · United Kingdom (3) · Egypt (2) · France (2) · Australia (1) · Belgium (1) · Greece (1) · Hungary (1) · Iraq (1)
Delphine L Chen, MD (2) · Muhammad Irfan Malik, FCPS (2) · Xiaolan Yong, Bachelor (2) · Aaron Weitzman (1) · Adam DuVall, MD (1) · Beatrice Stefanescu, MD, MS (1) · Bill Gurley, PhD (1) · Craig Selzman, MD (1) · David Alland, MD (1) · David Hager, MD PhD (1) · David Landers, MD (1) · Dean J Kereiakes, MD (1) · Delphine Chen, MD (1) · Dominicus Husada, MD (1) · Erika Saunders, MD (1)
PMID 34013969, PMID 36734509, PMID 37162745, PMID 15060237, PMID 18945956, PMID 19462133, PMID 19574441, PMID 21340319, PMID 23582727, PMID 23608625, PMID 24013700, PMID 24646034, PMID 25321315, PMID 25607427, PMID 25900158, PMID 26352946, PMID 26492219, PMID 27146253, PMID 27183377, PMID 27420164, PMID 28621712, PMID 29414995, PMID 32020029, PMID 32091533, PMID 32094336, PMID 32109013, PMID 32142651, PMID 32150618, PMID 32167747, PMID 32228809, PMID 32294342, PMID 32379955, PMID 32475230, PMID 32619759, PMID 32627860, PMID 32665041, PMID 32673071, PMID 33044747, PMID 33059771, PMID 33108255, PMID 33155953, PMID 33232211, PMID 33296901, PMID 33301246, PMID 33306989, PMID 33323376, PMID 33353987, PMID 33378609, PMID 33482902, PMID 33519466
R01AI185685 (1), R01HL151685 (1)